Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

Integrin αvβ8-mediated TGF-β1 activation regulates sustained response in immune thrombocytopenia after TPO-RA withdrawal

Heng Mei, Min Xu, Jinhui jin Shu, Lu Tang, Qinying Xie, Lili Luo, Qiuzhe Wei, Huiwen Jiang, Zhangyin Ming, Yu Hu

Blood blood.2025029769.

https://doi.org/10.1182/blood.2025029769

Published: 2025

Includes: Supplemental data

Journal Articles

Updated results from the Phase 1b/2 study of MK-1045, a novel CD19xCD3 T-cell engager, in adult participants with relapsed or refractory B-cell acute lymphoblastic leukemia

Ying Wang, Qingsong Yin, Jinhai Ren, Hongsheng Zhou, Tiejun Gong, Feng Zhu, Xi Zhang, Qin Wen, Heng Mei, Wei Huang, Zhenghong Chen, Bhargava Kandala, Jingxia Chen, Jianxiang Wang

Blood (2025) 146 (Supplement 1): 647.

https://doi.org/10.1182/blood-2025-647

Published: 2025

Journal Articles

TPO-ras for persistent thrombocytopenia following CAR-T therapy in multiple myeloma: A multicenter clinical experience

Yinqiang Zhang, Zhaozhao Chen, Yingying Li, Wei Xie, Chunrui Li, Heng Mei

Blood (2025) 146 (Supplement 1): 4077.

https://doi.org/10.1182/blood-2025-4077

Published: 2025

Journal Articles

A retrospective study on orelabrutinib combined with anti-CD20 monoclonal antibody regimen in treating mucosa-associated lymphoid tissue lymphoma.

Hongyong Zhang, Zhipeng Cheng, Yingying Wu, Chunyan Sun, Danying Liao, Guohui Cui, Linghui Xia, Yu Hu, Heng Mei, Jun Fang

Blood (2025) 146 (Supplement 1): 7130.

https://doi.org/10.1182/blood-2025-7130

Published: 2025

Journal Articles

BCMA-targeted CAR T cells for multi-refractory primary immune thrombocytopenia: A pilot study

Jinhui Shu, Min Xu, Wei Xie, Lin Liu, Qiuzhe Wei, Hongjian Li, Jishuai Zhang, Yu Hu, Heng Mei

Blood (2025) 146 (Supplement 1): 1267.

https://doi.org/10.1182/blood-2025-1267

Published: 2025

Journal Articles

Favorable Outcomes of Bridging Glofitamab Prior to anti-CD19 CAR-T cell Therapy in patients with non-Hodgkin lymphoma

Yinqiang Zhang, Lin Liu, Liman Su, Qiaolin Liu, Wei Xie, Heng Mei

Blood (2025) 146 (Supplement 1): 7261.

https://doi.org/10.1182/blood-2025-7261

Published: 2025

Journal Articles

Lipo-MIT-based bridging therapy enables effective CAR-T treatment in high-risk relapsed or refractory B-cell lymphoma

Yun Kang, Danying Liao, Wei Xie, Lin Liu, Yinqiang Zhang, Heng Mei

Blood (2025) 146 (Supplement 1): 5935.

https://doi.org/10.1182/blood-2025-5935

Published: 2025

Journal Articles

Inotuzumab ozogamicin vs blinatumomab bridging optimization and second CD19 CAR-T efficacy in Relapsed/Refractory B-ALL

Lin Liu, Danying Liao, Weijiayi Wang, Wei Xie, Jia Xu, Yinqiang Zhang, Fen Zhou, Heng Mei

Blood (2025) 146 (Supplement 1): 2398.

https://doi.org/10.1182/blood-2025-2398

Published: 2025

Journal Articles

A phase I monotherapy study assessing the safety and efficacy of GR1803, a BCMA×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma

Min Yang, Yang Liang, Guorong Wang, Baijun Fang, Luqun Wang, Songfu Jiang, Yafei Wang, Heng Mei, Wei Yang, Yanjuan He, Wei Wang, Haichao Zhang, Houguo Wang, Jie Jin, Wenming Chen

Blood (2025) 146 (Supplement 1): 5822.

https://doi.org/10.1182/blood-2025-5822

Published: 2025

Journal Articles

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)

Blood (2025) 146 (Supplement 1): 1042.

https://doi.org/10.1182/blood-2025-1042

Published: 2025

Journal Articles

Bendamustine combined with fludarabine/cyclophosphamide as a enhanced lymphodepletion regimen demonstrates favorable efficacy and safety in CAR-T therapy for extranodal/bulky R/R B-cell lymphoma

Cong Lu, Danying Liao, Lin Liu, Wei Xie, Yun Kang, Yinqiang Zhang, Heng Mei

Blood (2025) 146 (Supplement 1): 1950.

https://doi.org/10.1182/blood-2025-1950

Published: 2025

Journal Articles

Efficacy and safety of polatuzumab vedotin–based regimens in newly diagnosed diffuse large B-cell lymphoma: A single-center retrospective study

Taiyuan Zhang, Yingying Wu, Zhipeng Cheng, Ao Zhang, Lin Liu, Lu Zhang, Danying Liao, Wei Xie, Fang Liu, Guohui Cui, Yu Hu, Heng Mei, Jun Fang

Blood (2025) 146 (Supplement 1): 7207.

https://doi.org/10.1182/blood-2025-7207

Published: 2025

Journal Articles

CD7-targeted universal CAR T-cell therapy in relapsed or refractory (R/R) acute myeloid leukemia (AML): Clinical results from CTD401/402 studies

Yong-xian Hu, Xiaoyu Zhu, Heng Mei, Ying Wang, Yali Zhou, Kangqi Bian, Maria del Rosario, Eileen McNulty, Ming Gao, Lu Han, Wengang Ge, Jan Davidson-Moncada, Jiangtao Ren, He Huang

Blood (2025) 146 (Supplement 1): 816.

https://doi.org/10.1182/blood-2025-816

Published: 2025

Journal Articles

Indoleamine 2,3-dioxygenase 1 (IDO1) promotes immune effector cell-associated neurotoxicity syndrome (ICANS) after CAR-T therapy by disrupting brain endothelial cell integrity via KYNU–AA–Wnt/β-catenin pathway

Wanying Zhang, Zhaozhao Chen, Liman Su, Yingying Li, Jinhui Shu, Heng Mei

Blood (2025) 146 (Supplement 1): 807.

https://doi.org/10.1182/blood-2025-807

Published: 2025

Journal Articles

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with B-cell acute lymphoblastic leukemia: Insights from real-world data

Blood (2025) 146 (Supplement 1): 5122.

https://doi.org/10.1182/blood-2025-5122

Published: 2025

Journal Articles

Clinical outcomes and novel therapeutic strategies in adult patients with MLL-rearranged acute lymphoblastic leukemia: A monocentric retrospective analysis

Lin Liu, Yinqiang Zhang, Weijiayi Wang, Wei Xie, Mengyi Du, Fen Zhou, Heng Mei

Blood (2025) 146 (Supplement 1): 6890.

https://doi.org/10.1182/blood-2025-6890

Published: 2025

Journal Articles

CTA311, a universal anti-CD19 CAR t-cell therapy with improved persistence for patients with CD19+ relapsed/ refractory (R/R) b-cell acute lymphoblastic leukemia (B-ALL)

Guangyu Sun, Heng Mei, Anyou Wang, Tianzhong Pan, Yali Zhou, Gong Chen, Jiuqin Zeng, Kangqi Bian, Jan Davidson-Moncada, Bo Pei, Lu Han, Jiangtao Ren, Xiaoyu Zhu

Blood (2025) 146 (Supplement 1): 5920.

https://doi.org/10.1182/blood-2025-5920

Published: 2025

Journal Articles

Hetrombopag for patients with persistent primary immune thrombocytopenia: A post-hoc analysis of a multicenter, randomized phase Ⅲ Trial

Blood (2025) 146 (Supplement 1): 4812.

https://doi.org/10.1182/blood-2025-4812

Published: 2025

Journal Articles

Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: Results from a randomized, multicenter, placebo-controlled phase 3 trial

Runhui Wu, Ju Gao, Yufeng Liu, Jie Yu, Shaoyan Hu, Hui Liang, Hui Jiang, Xiaowen Zhai, Min Zhou, Wenge Hao, Heng Mei, Fei Li, Yumei Chen, Wei Liu, Mei Yan, Runzi Li, Junye Xiong, Zhenyi Zhu, Tianyou Wang

Blood (2025) 146 (Supplement 1): 4804.

https://doi.org/10.1182/blood-2025-4804

Published: 2025

Journal Articles

Line-of-therapy stratified efficacy of belumosudil in cgvhd : Real-world evidence

Yaogong Wu, Zhaodong Zhong, Jiawen Wang, Huanpeng Zhu, Heng Mei

Blood (2025) 146 (Supplement 1): 7748.

https://doi.org/10.1182/blood-2025-7748

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Integrin αvβ8-mediated TGF-β1 activation regulates sustained response in immune thrombocytopenia after TPO-RA withdrawal

Updated results from the Phase 1b/2 study of MK-1045, a novel CD19xCD3 T-cell engager, in adult participants with relapsed or refractory B-cell acute lymphoblastic leukemia

TPO-ras for persistent thrombocytopenia following CAR-T therapy in multiple myeloma: A multicenter clinical experience

A retrospective study on orelabrutinib combined with anti-CD20 monoclonal antibody regimen in treating mucosa-associated lymphoid tissue lymphoma.

BCMA-targeted CAR T cells for multi-refractory primary immune thrombocytopenia: A pilot study

Favorable Outcomes of Bridging Glofitamab Prior to anti-CD19 CAR-T cell Therapy in patients with non-Hodgkin lymphoma

Lipo-MIT-based bridging therapy enables effective CAR-T treatment in high-risk relapsed or refractory B-cell lymphoma

Inotuzumab ozogamicin vs blinatumomab bridging optimization and second CD19 CAR-T efficacy in Relapsed/Refractory B-ALL

A phase I monotherapy study assessing the safety and efficacy of GR1803, a BCMA×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)

Bendamustine combined with fludarabine/cyclophosphamide as a enhanced lymphodepletion regimen demonstrates favorable efficacy and safety in CAR-T therapy for extranodal/bulky R/R B-cell lymphoma

Efficacy and safety of polatuzumab vedotin–based regimens in newly diagnosed diffuse large B-cell lymphoma: A single-center retrospective study

CD7-targeted universal CAR T-cell therapy in relapsed or refractory (R/R) acute myeloid leukemia (AML): Clinical results from CTD401/402 studies

Indoleamine 2,3-dioxygenase 1 (IDO1) promotes immune effector cell-associated neurotoxicity syndrome (ICANS) after CAR-T therapy by disrupting brain endothelial cell integrity via KYNU–AA–Wnt/β-catenin pathway

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with B-cell acute lymphoblastic leukemia: Insights from real-world data

Clinical outcomes and novel therapeutic strategies in adult patients with MLL-rearranged acute lymphoblastic leukemia: A monocentric retrospective analysis

CTA311, a universal anti-CD19 CAR t-cell therapy with improved persistence for patients with CD19+ relapsed/ refractory (R/R) b-cell acute lymphoblastic leukemia (B-ALL)

Hetrombopag for patients with persistent primary immune thrombocytopenia: A post-hoc analysis of a multicenter, randomized phase Ⅲ Trial

Efficacy and safety of hetrombopag, a novel thrombopoietin receptor agonist, in children and adolescents with immune thrombocytopenia: Results from a randomized, multicenter, placebo-controlled phase 3 trial

Line-of-therapy stratified efficacy of belumosudil in cgvhd : Real-world evidence

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only